C
한올바이오파마
009420KOSPI의약품 제조업41.7 / 100
Reference Date: 2026-04-13
Financial Score10.0 / 40
News Sentiment13.7 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Plunged 16.2% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Hanall BioPharma, established in 1973, focuses on R&D, manufacturing, and sales of synthetic and biopharmaceuticals, with a particular emphasis on developing new drugs for autoimmune diseases, eye conditions, cancer, and neurological disorders. In 2024, the company reported revenue of 138.9 billion KRW, with its subsidiary HPI handling overseas clinical trials and licensing activities.
Number of Employees
315people
Average Salary
82.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 14.804.0Point
PBR
15.23Industry Average 1.040.0Point
14.6x industry avg (risky)
ROE
-3.37Industry Average 4.420.0Point
Well below industry avg
Debt Ratio
11.80Industry Average 11.984.0Point
In line with industry avg
Trend 2023~20252.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲7.3% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼293.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -0.8% (declining, 3yr)
Detailed News Sentiment
25 totalPositive 0Neutral 20Negative 0Average Sentiment Score 56
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position5.0Point
52w mid range (57%)
Current 47,150Won52-week high 64,40052-week low 24,250
1-month return0.0Point
1m -16.25% (strong drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
6 totalPositive 0Neutral 6Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-07
- Neutral주식등의대량보유상황보고서(약식)2026-04-01
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
- Neutral대표이사(대표집행임원)변경(안내공시)2026-03-26
- Neutral정기주주총회결과2026-03-26